ClinicalTrials.gg
RecruitingNCT06755541Updated Jan 8, 2026

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

A Phase 3 interventional study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis (PBC), sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2024, registered Dec 2024).
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.

Planned enrollment
3rd of 13
150 · median 117
Started
2024
with 2 others
Phase 3
6 of 13
5 open now
Registered
10th of 13
by date
Lead sponsor
9 of 13
Xijing Hospital of Digestive Diseases

Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 6 in phase 3, and was the 10th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, or all of them as a file.
02

Study summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated)
  2. Completed in a PBC study with fenofibrate(NCT05751967)
  3. Females of must use at least one barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

  1. Treatment-related adverse event (AE) leading to study drug discontinuation in a previous PBC study with seladelpar
  2. A medical condition, other than PBC, that in the Investigator's opinion would preclude full participation in the study or confound its results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    fenofibrate

    Experimental: Fenofibrate 200 mg Capsules

    Drug: Fenofibrate in Combination With Ursodeoxycholic Acid

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events (TEAEs)

    Time frame: Through study completion, up to 120 Months

Secondary outcomes

  1. Death

    Occurrence of overall death

    Time frame: 120 months

  2. Liver transplantation

    Occurrence of overall liver transplantation

    Time frame: 120 months

  3. Normalization of ALP

    Proportion of subjects with normalization of ALP

    Time frame: 120 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2035, 143 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 1, 2025
StartActual
Jan 30, 2024
Primary completionEst.
Dec 2035
CompletionEst.
Dec 2035
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06755541
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Han Ying (Professor, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Jan 1, 2025
Start date
Jan 30, 2024
Primary completion
Dec 2035 (estimated)
Completion
Dec 2035 (estimated)
Last update
Jan 8, 2026

Study contacts

Yansheng Liu
Contact
liuyansheng506@163.com
862984771539

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Ursodeoxycholic Acid

Start the discussion